IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been given an average rating of “Moderate Buy” by the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $53.58.

IDYA has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Stephens reiterated an “overweight” rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th.

IDEAYA Biosciences Stock Up 1.6 %

Shares of NASDAQ:IDYA opened at $20.57 on Friday. The business has a fifty day moving average of $23.30 and a two-hundred day moving average of $28.71. The stock has a market cap of $1.80 billion, a P/E ratio of -6.23 and a beta of 0.82. IDEAYA Biosciences has a 52-week low of $19.95 and a 52-week high of $47.72.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. On average, equities analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV boosted its holdings in IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after acquiring an additional 513 shares during the period. Amalgamated Bank boosted its holdings in IDEAYA Biosciences by 22.9% during the 3rd quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock valued at $90,000 after acquiring an additional 530 shares during the period. Rhumbline Advisers raised its position in IDEAYA Biosciences by 0.5% in the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after purchasing an additional 585 shares in the last quarter. US Bancorp DE raised its position in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in IDEAYA Biosciences by 35.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock valued at $94,000 after purchasing an additional 796 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.